Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625906 | 0.98 | CYP19A1 (0.37) | NR1H2NR1H3CYP19A1AHRCYP3A4 | |
| SCHEMBL4625813 | 0.98 | CYP19A1 (0.37) | NR1H2NR1H3CYP19A1AHRCYP3A4 | |
| SCHEMBL4626920 | 0.94 | AHR (0.43) | CYP19A1AHRACSS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4624707 | 0.94 | AHR (0.43) | CYP19A1AHRACSS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4624733 | 0.93 | AHR (0.42) | CYP19A1AHRACSS2SMN1; SMN2KMT2A | |
| SCHEMBL4626091 | 0.81 | ALDH1A1 (0.35) | MAPTTDP1ALDH1A1KMT2A | |
| SCHEMBL4625876 | 0.80 | ELANE (0.49) | — | |
| SCHEMBL4627027 | 0.79 | KIF11 (0.41) | AHRTDP1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL4627743 | 0.79 | ELANE (0.51) | TDP1ALDH1A1 | |
| SCHEMBL14230792 | 0.76 | MAPT (0.41) | NR1H2CYP19A1CYP3A4CYP3A5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401851-B1 | TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS | FEBIT BIOTECH GMBH (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-7355036-B2 | Two-stage protective groups for the synthesis of biopolymers | FEBIT AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | MR. CHRISTOPHER SEAGON, ESQ. (DE) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | CTRB2, OGG1, CPB2 | NR1H2 4755/4885NR1H3 4816/4885CYP19A1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.